Literature DB >> 22846118

Comparison of clinical characteristics between healthcare-associated pneumonia and community-acquired pneumonia in patients admitted to secondary hospitals.

Jong Hoo Lee1, Yee Hyung Kim.   

Abstract

BACKGROUND: Since healthcare-associated pneumonia (HCAP) is heterogeneous, clinical characteristics and outcomes are different from region to region. There can also be differences between HCAP patients hospitalized in secondary or tertiary hospitals. This study aimed to evaluate the clinical characteristics of HCAP patients admitted into secondary community hospitals.
METHODS: This was a retrospective study conducted in patients with HCAP or community-acquired pneumonia (CAP) hospitalized in two secondary hospitals between March 2009 and January 2011.
RESULTS: Of a total of 303 patients, 96 (31.7%) had HCAP. 42 patients (43.7%) resided in a nursing home or long-term care facility, 36 (37.5%) were hospitalized in an acute care hospital for ≥ 2 days within 90 days, ten received outpatient intravenous therapy, and eight attended a hospital clinic or dialysis center. HCAP patients were older. The rates of patients with CURB-65 scores of 3 or more (22.9% vs. 9.1%; p=0.001) and PSI class IV or more (82.2% vs. 34.7%; p<0.001) were higher in the HCAP group. Drug-resistant pathogens were more frequently detected in the HCAP group (23.9% vs. 0.4%; p<0.001). However, Streptococcus pneumoniae was the most common pathogen in both groups. The rates of antibiotic change, use of inappropriate antibiotics, and failure of initial antibiotic therapy in the HCAP group were significantly higher. Although the overall survival rate of the HCAP group was significantly lower (82.3% vs. 96.8%; p<0.001), multivariate analyses failed to show that HCAP itself was a prognostic factor for mortality (p=0.826). Only PSI class IV or more was associated with increased mortality (p=0.005).
CONCLUSIONS: HCAP should be distinguished from CAP because of the different clinical features. However, the current definition of HCAP does not appear to be a prognostic for death. In addition, the use of broad-spectrum antibiotics for HCAP should be reassessed because S. pneumoniae was most frequently identified even in HCAP patients.
Copyright © 2012 Elsevier Editora Ltda. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22846118     DOI: 10.1016/j.bjid.2012.06.019

Source DB:  PubMed          Journal:  Braz J Infect Dis        ISSN: 1413-8670            Impact factor:   1.949


  5 in total

1.  Nasopharyngeal Carriage of Streptococcus Pneumoniae and Serotypes Indentified among Nursing Home Residents in Comparison to the Elderly and Patients Younger than 65 Years Living in Domestic Environment.

Authors:  Maja Kolšek-Šušteršič; Andreja Beg Krasnič; Verica Mioč; Metka Paragi; Janez Rifel
Journal:  Zdr Varst       Date:  2017-05-26

2.  Long-term mortality of hospitalized pneumonia in the EPIC-Norfolk cohort.

Authors:  P K Myint; K R Hawkins; A B Clark; R N Luben; N J Wareham; K-T Khaw; A M Wilson
Journal:  Epidemiol Infect       Date:  2015-08-24       Impact factor: 2.451

Review 3.  Microbiology of healthcare-associated infections and the definition accuracy to predict infection by potentially drug resistant pathogens: a systematic review.

Authors:  Teresa Cardoso; Mónica Almeida; Jordi Carratalà; Irene Aragão; Altamiro Costa-Pereira; António E Sarmento; Luís Azevedo
Journal:  BMC Infect Dis       Date:  2015-12-11       Impact factor: 3.090

Review 4.  Classification of healthcare-associated infection: a systematic review 10 years after the first proposal.

Authors:  Teresa Cardoso; Mónica Almeida; N Deborah Friedman; Irene Aragão; Altamiro Costa-Pereira; António E Sarmento; Luís Azevedo
Journal:  BMC Med       Date:  2014-03-06       Impact factor: 8.775

5.  Hospital utilization rates for influenza and RSV: a novel approach and critical assessment.

Authors:  Emily K Johnson; Dillon Sylte; Sandra S Chaves; You Li; Cedric Mahe; Harish Nair; John Paget; Tayma van Pomeren; Ting Shi; Cecile Viboud; Spencer L James
Journal:  Popul Health Metr       Date:  2021-06-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.